Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 0.60 |
| ▸ | CPT1A | P50416 | 3/20 | 0.60 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL1580890 | 0.95 | CPT2 (0.57) | CPT2CPT1ACPT1BEPHX1MAPT | |
| SCHEMBL12304894 | 0.94 | CPT2 (0.66) | CPT2CPT1ACPT1BEPHX1EPHX2 | |
| SCHEMBL13522724 | 0.88 | CPT2 (0.51) | CPT2CPT1ACPT1BEPHX1MAPT | |
| SCHEMBL12304891 | 0.85 | CPT2 (0.47) | CPT2CPT1ACPT1BEPHX2 | |
| SCHEMBL12304896 | 0.84 | CPT2 (0.67) | CPT2CPT1ACPT1BEPHX1MAPT | |
| SCHEMBL12304909 | 0.84 | CPT2 (0.67) | CPT2CPT1ACPT1BEPHX1MAPT | |
| SCHEMBL1580325 | 0.84 | CPT2 (0.61) | CPT2CPT1ACPT1BEPHX1MAPT | |
| Formic Acid SCHEMBL1580380 | 0.83 | CPT2 (0.49) | CPT2CPT1ACPT1BEPHX1MAPT | |
| SCHEMBL1579627 | 0.83 | CPT2 (0.86) | CPT2CPT1ACPT1B | |
| SCHEMBL2453804 | 0.83 | CPT2 (0.86) | CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | DARA BIOSCIENCES, INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010008473-A1 | ENZYME INHIBITORS AND THE USE THEREOF | DARA BIOSCIENCES, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | GAA, CYP17A1, HSD17B11 | CPT2 1556/4885CPT1A 466/4885CPT1B 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.